abstract |
Cardiovascular diseases, particularly essential hypertension, pulmonary hypertension and the like, relating to the administration of a synergistic combination of at least one neutral endopeptidase, at least one endogenous endothelin production system inhibitor and at least one AT 1 receptor antagonist A novel combination therapy for congestive heart failure is described. |